BioCentury
ARTICLE | Clinical News

ConXn recombinant relaxin data

January 13, 1997 8:00 AM UTC

CNCT announced that Phase I results show good toleration with no serious adverse events. Improved skin scores also were achieved. The product is in Phase II testing in this indication.

The skin scores, a measure of skin thickening used as an end point for scleroderma, is associated with the hardening of skin and internal organs that occurs during the disease. Of the 11 evaluable patients in the open-label trial, 10 had improved scores, 6 of whom showed a 35 percent mean improvement. Four others showed 12 percent mean improvement. Scores worsened in 1 patient by 6 percent. More details will be presented at the April meeting of the British Society for Rheumatology. ...